Latest news

• Sanofi extends growth spurt thanks to Genzyme, Dupixent

  atopic dermatitis drug Dupixent providing the acceleration in its Q4 results. ... Genzyme had a solid quarter with sales up almost 11% to 794m, while Dupixent (dupilumab) added another 280m, more than double the same period of 2017, fuelled in part by a

• As France protests, Sanofi takes axe to 670 jobs

  dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

• Orphan drugs from Biogen and Amicus win UK Prix Galien

  Sanofi’s treatment for moderate-to-severe atopic dermatitis Dupixent was highly commended in the same category.

• Dupixent helps put Sanofi back on growth track

  and delivered on its promise thanks to a surge in sales for atopic dermatitis drug Dupixent. ... Dupixent (dupilumab) – which has also just been approved for asthma – saw sales almost triple to 225m in the three-month period, helping Sanofi’s net

• AZ, Amgen’s first-in-class asthma drug gets breakthrough status

  Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic dermatitis. ... Dupixent was filed for asthma in the US in March and is due for an FDA verdict by 20 October, but some analysts have said